Current snake antivenoms are unsafe and expensive. Viper Therapeutics has a novel, safe, and effective solution to this global unmet need.
The global supply of snake antivenoms currently consists of inferior products, in terms of both safety and efficacy, which are derived from animal serum. Viper Therapeutics has developed a novel platform for producing human antibody based snake anti-venoms to create safe and renewable treatments for snake envenomation. This platform will fill a global unmet public health need and has a potential multi-billion dollar market.